Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Corbet XT is a branded generic hematinic combination product marketed by Sinsan Pharmaceuticals. It is primarily indicated for the treatment and prevention of iron deficiency anemia and associated nutritional deficiencies. The formulation typically consists of Carbonyl Iron, Folic Acid (Vitamin B9), and Zinc Sulphate. Carbonyl Iron provides a high concentration of elemental iron with a lower toxicity profile and better gastrointestinal tolerance compared to traditional ferrous salts. Folic Acid is a critical coenzyme for DNA synthesis and the maturation of red blood cells, while Zinc Sulphate serves as an essential trace element and cofactor for numerous enzymes involved in immune function and cellular metabolism. The 'XT' suffix in the Indian pharmaceutical market typically denotes an extended-release formulation, designed to optimize absorption and minimize side effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Corbet XT.